Popular Articles

Celleron Therapeutics And Astrazeneca Announce Personalised Medicine Collaboration In Cancer For The Development Of AZ's Leading HDAC Inhibitor
Celleron Therapeutics Ltd, the Oxford UK based specialist in the development of individually targeted cancer medicines, has secured exclusive rights to AstraZeneca plc"s lead histone deacetylase (HDAC) inhibitor (AZD 9468), for global development in conjunction with its proprietary "CancerNav" predictive biomarker platform. "CancerNav" specifically identifies those tumours which are most likely to respond to an individual cancer drug, thereby enabling a highly focussed clinical development and commercialisation programme, based on a closely linked diagnostic and therapeutic "personalised medicine" approach.

Buy lamisil to treat nail fungus.
Array BioPharma Announces Top-Line Results In Two Phase 1 Clinical Trials
Array BioPharma Inc. (NASDAQ: ARRY) announced top-line results from its Phase 1 seven-day dose escalation trial up to 1,200 mg daily of p38 inhibitor, ARRY-797, in healthy volunteers. In addition, the top-line results were announced in a second study, where ARRY-797 was evaluated in a 28-day Phase 1b trial in stable rheumatoid arthritis (RA) patients taking methotrexate. This study compared two doses of ARRY-797 to placebo.
News of the day
Women Previously Diagnosed With Cervical Intraepithelial Neoplasia At Higher Risk For Recurrence And Invasive Cancer
Long-term risks of invasive cancer and recurrence of severe cervical intraepithelial neoplasia (CIN) are higher among women previously treated for CIN, compared with those with no CIN diagnosis, according to data from a large, retrospective cohort study published in the May 12 online issue of the Journal of the National Cancer Institute.

New Plans To Improve Eating Disorder Services In Wales.

Two new specialist teams will be set up to improve diagnosis, care and support for people with eating disorders in Wales, Health Minister Edwina Hart officially announced. The new teams - for North Wales and South Wales - will comprise of specialist clinicians and work closely with existing services such as GPs surgeries, social services, child and adolescent mental health services and community mental health teams. Additional funding has been allocated to deliver this plan. ÷£0.5 million will be available this year for the recruitment of additional staff and extra training. After that, ÷£1 million will be available every year to sustain and develop services. stucco Toronto

Swine Flu Daily Update Issued At: 11am Friday 10 July 2009, Wales.

The NPHS influenza surveillance scheme, which records reports of diagnoses of flu from more than 300 GP practices across Wales, shows low levels of influenza activity in all parts of Wales. Further detail can be found on the NPHS website: http://www.wales.nhs.uk/sites3/page.cfm?orgid=457&pid=38241 -- The report from 8 July estimates there were 12.2 cases of a flu-like illness diagnosed by GPs out of every 100,000 people in Wales - this is the equivalent of 366 people in Wales contacting their GPs in the last seven days with flu like symptoms. Not all of these people will have swine flu and not everyone with flu like symptoms will contact their GP. It is expected that the proportion of influenza cases diagnosed that are due to swine flu will increase as the virus spreads in Wales. plasma cutting table

Bayer Unveils DIDGET(TM), The First And Only Blood Glucose Meter That Connects With The Nintendo DS(TM) Or DS(TM) Lite.

Bayer Diabetes Care in the UK and Ireland today unveils "DIDGET(TM), the first and only blood glucose meter for kids with diabetes that connects directly to Nintendo DS(TM) and Nintendo DS(TM) Lite gaming systems. The DIDGET meter is designed to help kids manage this lifelong condition by rewarding them for building consistent blood glucose testing habits and meeting personalised glucose target ranges. "One of the biggest challenges facing parents of children with diabetes is the constant struggle to instil the habit of regular blood glucose testing that is critical for consistent diabetes management," says John Gregory, Professor in Paediatric Endocrinology, Wales School of Medicine, Cardiff University. "Bayer"s DIDGET meter can help ease the parent/child tension that testing often creates by adding an element of fun and rewards to the routine. Because it is designed with children in mind, Bayer"s DIDGET meter can transform a child"s blood glucose testing experience from something they have to do into something they want to do.

NovImmune Successfully Completes NI-0801 Phase I Clinical Study.

NovImmune, an immunology-focused biotech company dedicated to the development of therapeutic monoclonal antibodies, announced the successful completion of the first phase I clinical study with its fully human monoclonal antibody NI-0801 targeting the chemokine IP-10 (CXCL10) in healthy volunteers. The randomized, doubleblinded, placebo controlled, single centre, phase I study of escalating single intravenous doses of NI-0801 in healthy volunteers (study NI-0801-01) demonstrated that NI-0801 is well tolerated at doses up to and including 20mg/kg. Chemokines are a group of low molecular weight proteins that induce the chemotaxis of different leukocytes to sites of injury or infection. basement contractor toronto